Investigational new drugs applications for

Patents have issued for the use of amino-acid complexes [253], copper-metallothioneins [254], compositions of copper compounds mixed with fatty acids [253], copper complexes of D-penicillamine, alkylcysteines [256, 257] and copper complexes offatty acids alone or mixed with metallic copper [258]. Compositions of copper compounds mixed with fatty acids were also claimed to be useful in the treatment of other inflammatory disorders, including cardiovascular and thrombotic disorders, menstrual cycle disorders, diabetes, endometriosis, nutritional deficiencies and malignancies [255]. Scheinberg has also obtained a Food and Drug Administration approved Investigational New Drug application for the treatment of RA with the mixed-valence copper penicillamine complex (personal communication). Preparations of Cu(II)-(oleate) are currently being sold in Europe for topical treatment of RA and other inflammatory disorders under the trade names of Kupfer and Kupfer Forte, which contains fine particles of metallic copper [258]. 

Requests for permission to conduct clinical trials with pharmaceuticals in the US are termed Investigational New Drug Applications (INDs). The applications are actually a request for an exemption to supply a drug without a marketing authorisation. A cover sheet (Form 1571) must accompany the application. This cover sheet should also be used with each subsequent communication with the FDA, with each form consecutively numbered, starting at 000 for the initial submission. A copy of the form is shovm in Figure 5.6. 

Asphalt chemicals, ethyleneamines application, 8 500t, 506 Asphalt emulsifier amine oxides, 2 473 fatty acid amides, 2 458 Asphalt emulsions, 10 131 Asphaltenes, in petroleum vacuum residua, 18 589-590 Asphyxiants, 21 836 Aspirating aerators, 26 165-169 compressed, 26 168-169 propeller driven, 26 168 submersible, 26 169, 170t subsurface, 26 168 Aspiratory, 11 236-237 Aspirin, 4 103-104, 104t, 701 22 17-21. See also Acetylsalicylic acid as trade name, 22 19 for cancer prevention, 2 826 Aspirin resistance, 4 104 ASP oil recovery process, 23 532-533 Assay format, competitive, 14 142 Assay limits, in Investigational New Drug Applications, 18 692 Assays, for silver, 22 650. See also... 

Investigator s Brochure, in Investigational New Drug Applications, 25 691 Investigator information, for Investigational New Drug Applications, 25 690 Investment... 

Lumpkin, M. (1996). Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including well-characterized, therapeutic, and biotechnology-derived products, http //www.fda.gov/cder/guidance/phasel.pdf... 

IND Investigational New Drug application, filed with FDA after preclinical testing is complete asking for permission to proceed with human tests. 

The FDA regulations or guidelines prescribe the types of safety tests for a particular product. Sponsors may conduct the studies in their own laboratories or have them performed by a contract laboratory, a university, or some other type of laboratory. The sponsor submits the study reports to the FDA in food and color additive petitions, investigational new drug applications, new drug applications, new animal drug applications, biological product license applications, and other requests for permission to market a product. 

An investigational new drug application (IND) outlines what the sponsor of a new drug proposes for human testing in clinical trials. 

A standard toxicology package was developed for tasidotin for filing the Investigational New Drug Application with the Food and Dmg Administration (FDA). Single-dose studies under the proposed route of administration (IV) were initiated... 

The FDA is responsible for the review and market approval of new drugs, biologies, and medical devices in the United States under the authority of the Federal Food Drug and Cosmetic Act (the Act) and Section 351 of the Public Health Service Act (the PHS Act). The FDA defines premarket review as the examination of data and information in an application as described in Sections 505, 510(k), 513(f), 515, or 520(g) or 520(1) of the Act or Section 351 of the PHS Act. This refers to the premarket review of data and information contained in any Investigational New Drug application (IND), Investigational Device... 

---